Navigation Links
Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
Date:9/7/2010

unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause material differences include, among others, risks relating to: the successful preclinical development of our product candidates; the completion of our clinical trials; the review process of the FDA, the EMEA, other foreign regulatory bodies and other governmental regulatory bodies, including the FDA's and the EMEA's review of any filings we make in connection with the treatment protocol for taliglucerase alfa and including the risk that regulatory authorities may find that the data from our clinical trials and other studies is insufficient for regulatory approval; delays in the FDA's, the EMEA's or other health regulatory authorities' approval of any applications we file or refusals to approve such filings, including the NDA we filed with the FDA for taliglucerase alfa for the treatment of Gaucher disease; refusals by such regulatory authorities to approve the marketing and sale of a drug product even after acceptance of an application we file for any such drug product; and other factors described in our filings with the Securities and Exchange Commission.  Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary findings for such clinical trials.  Further, even if favorable testing data is generated by clinical trials of drug products, the FDA, EMEA or any other foreign regulatory authority may not accept or approve an NDA filed by a pharmaceutical or biotechnology company for such drug product.  Failure to obtain approval from the FDA, EMEA or any other foreign regulatory a
'/>"/>
SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
2. Protalix Announces Successful GMP Manufacturing Audit by Israels Ministry of Health
3. Talecris Biotherapeutics to Report Second Quarter 2010 Financial Results
4. Talecris Biotherapeutics Announces Premerger HSR Filing
5. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
6. Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
7. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
8. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
9. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
10. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
11. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Independent ... County), California, and Montreal, Canada, has big ideas for ... non-fiction. The press's goals are to produce high-quality, low-cost, ... to support local businesses. , The first major ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... to Additional Capital Will Enable Revenue Growth, ... Bulletin Board: BLFS), a leading developer and marketer ... tissues, and organs, today announced that it reached ... to increase the Company,s,existing credit facility from $5 ...
... that NanoBio,s nanoemulsion technology is effective when ... used in therapeutic applications and vaccines, ANN ... it will present compelling new data in nine presentations ... programs,in onychomycosis, herpes labialis, cystic fibrosis and an intra-nasal,influenza ...
... NxStage Medical,Inc. (Nasdaq: NXTM ), a ... its Medisystems Division has signed a,long-term product supply ... provider of dialysis services in the United States. ... the Streamline(TM) airless,blood tubing set as well as ...
Cached Biology Technology:BioLife Solutions Credit Facility Increased to $9 Million 2NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008 2NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc. 2NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc. 3
(Date:7/9/2014)... pivotal in the development of cancer, viral infection and ... question about one of the most widely-researched proteins in ... of thousands of research papers and millions of pounds ... in Professor Sir Philip Cohen,s laboratory at the University ... is activated. The results are published today ...
(Date:7/9/2014)... ability to switch out one gene for another in ... from science fiction to reality within this decade. As ... promise--the hope of fixing disease-causing genes in humans, for ... scientists have put one of those concerns to rest: ... overall occurrence of mutations in the cells. The new ...
(Date:7/9/2014)... geographic ranges in which animals can be found, concern ... Does an increased range for a host mean new ... says a team of UC Santa Barbara scientists, including ... published in the Journal of Biogeography , Hechinger, ... opposite may happen: Hosts may actually lose their parasites ...
Breaking Biology News(10 mins):Research reveals how key controller protein is switched on 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Not at home on the range 2Not at home on the range 3Not at home on the range 4
... the humble honey bee, researchers at the University of ... understanding the molecular basis of social behavior in humans. ... a model system for social behavior," said Saurabh (pronounced ... affiliate of the university's Institute for Genomic Biology. Using ...
... Children with cancer who suffer hearing loss due to the ... get their hearing back through pharmacological and gene therapy, thanks ... Research Hospital. Mice with a variety of genetic mutations that ... understand age-related hearing loss in adults, as well as hearing ...
... cause of blindness in western society, say experts at The ... eye instrument, they have launched a study to see if ... also explain why the 77-year-old sailor has no need for ... and broccoli are rich in a chemical called lutein, which, ...
Cached Biology News:Honey bee genome holds clues to social behavior 2St. Jude finds clues to hearing loss from chemotherapy 2Why Popeye only has eyes for spinach 2
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Biology Products: